EVLO vs. SYRS, VRPX, SCPS, CMRA, GNCAQ, GNCA, ARDS, STAB, NMTR, and AMPE
Should you be buying Evelo Biosciences stock or one of its competitors? The main competitors of Evelo Biosciences include Syros Pharmaceuticals (SYRS), Virpax Pharmaceuticals (VRPX), Scopus BioPharma (SCPS), Comera Life Sciences (CMRA), Genocea Biosciences (GNCAQ), Genocea Biosciences (GNCA), Aridis Pharmaceuticals (ARDS), Statera Biopharma (STAB), 9 Meters Biopharma (NMTR), and Ampio Pharmaceuticals (AMPE). These companies are all part of the "pharmaceutical products" industry.
Evelo Biosciences vs. Its Competitors
Evelo Biosciences (NASDAQ:EVLO) and Syros Pharmaceuticals (NASDAQ:SYRS) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, valuation, earnings, profitability, dividends, risk, analyst recommendations and institutional ownership.
Syros Pharmaceuticals has a consensus target price of $1.00, indicating a potential upside of 30,203.03%. Given Syros Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Syros Pharmaceuticals is more favorable than Evelo Biosciences.
Evelo Biosciences has higher earnings, but lower revenue than Syros Pharmaceuticals.
In the previous week, Syros Pharmaceuticals had 1 more articles in the media than Evelo Biosciences. MarketBeat recorded 1 mentions for Syros Pharmaceuticals and 0 mentions for Evelo Biosciences. Syros Pharmaceuticals' average media sentiment score of 1.00 beat Evelo Biosciences' score of 0.00 indicating that Syros Pharmaceuticals is being referred to more favorably in the news media.
Evelo Biosciences has a beta of 0.79, meaning that its stock price is 21% less volatile than the S&P 500. Comparatively, Syros Pharmaceuticals has a beta of 1.31, meaning that its stock price is 31% more volatile than the S&P 500.
0.3% of Evelo Biosciences shares are held by institutional investors. Comparatively, 91.5% of Syros Pharmaceuticals shares are held by institutional investors. 1.0% of Evelo Biosciences shares are held by insiders. Comparatively, 12.3% of Syros Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Evelo Biosciences' return on equity of 0.00% beat Syros Pharmaceuticals' return on equity.
Summary
Syros Pharmaceuticals beats Evelo Biosciences on 8 of the 11 factors compared between the two stocks.
Get Evelo Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for EVLO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding EVLO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Evelo Biosciences Competitors List
Related Companies and Tools
This page (NASDAQ:EVLO) was last updated on 8/15/2025 by MarketBeat.com Staff
MarketBeat All Access